<DOC>
	<DOCNO>NCT02547558</DOCNO>
	<brief_summary>To evaluate pulmonary gas exchange response therapeutic high dose inhale indacaterol ( 300 mcg ) 20 outpatient stable symptomatic COPD B D GOLD 2011 group . Measurements single day 60 120 minute indacaterol include arterial PO2 , PaCO2 pH . AaPO2 ; SaO2 ( pulse oximetry ) oxygen carbon dioxide exhale breath , systemic arterial pressure heart rate also measured/calculated . Cardiac output directly measure bio-impedance .</brief_summary>
	<brief_title>Pulmonary Gas Exchange Response Indacaterol COPD</brief_title>
	<detailed_description>The investigator hypothesize stable chronic obstructive pulmonary disease ( COPD ) patient interaction intrapulmonary extrapulmonary determinant contribute gas exchange abnormality indacaterol ultimately preserve arterial oxygenation ( primary end-point outcome ) . The study include 20 outpatient diagnosis stable COPD GOLD 2011 group B D ( 10 ) , without frequent exacerbation ( ≥2 previous year ) . Patients COPD exacerbation within 3 month study , use long-term oxygen therapy associate condition serious comorbidities ( i.e. , asthma , bronchiectasis , lung cancer and/or cardiovascular disease ) exclude . Each patient study single day . All subject remain regular treatment study . Subjects require withhold SABAs least 12 h LABAs theophylline least 24 h study . During measurement , patient breath room air seat armchair . Measurements perform 60 120 min single dose administration indacaterol Breezhaler @ 300 mcg ( 1 inhalation ) . After ensure steady-state condition , assess stability ( ± 5 % ) ventilatory hemodynamic variable , close agreement ( within ± 5 % ) duplicate mixed expire arterial oxygen carbon dioxide , set duplicate measurement variable obtained time point . Blood sample collect catheter insert local anesthesia radial artery . Samples blood ( 5 ml ) remove measurement arterial O2 tension ( PaO2 ) , CO2 tension ( PaCO2 ) pH ; alveolar-arterial PO2 difference ( A-a ) DO2 , oxygen saturation ( SaO2 ) , VO2 , VCO2 , Ve , respiratory rate ( f ) , systemic arterial pressure ( Psa ) , heart rate ( HR ) measure calculate , previously describe . Cardiac output directly measure bio-impedance . Spirometry value record history record patient . All measurement perform Centre de Diagnòstic Respiratori ( CDR ) , Servei de Pneumologia , Institut del Tòrax , Hospital Clínic , Barcelona . The primary outcome PaO2 change indacaterol analysis time . Based previous study stable severe COPD patient use nebulized salbutamol convalescence exacerbation , Polverino et al . calculate significant PaO2 fall order 8 mmHg , sample 6 subject need ; number increase 20 patient ensure good data . Secondary outcome change PaCO2 , pH , calculate D ( A-a ) DO2 response cardiac output . Results express mean ( ±SEM ) median ( 95 % CI ) . The effect indacaterol end-point variable assess one-way repeated measure analysis variance ( ANOVA ) . Paired test Pearson 's correlation test use appropriate . All significance set p &lt; 0.05 , without correction multiple test .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Outpatients COPD diagnosis accord GOLD 2011 criterion ( VEF1/CVF less 70 % ) , group B D. Conditions serious comorbidities ( i.e. , asthma , bronchiectasis , lung cancer and/or cardiovascular disease ) . Patients frequent exacerbation ( 2 exacerbation past year ) . History acute COPD exacerbation previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Pulmonary gas exchange</keyword>
	<keyword>Long-acting bronchodilator</keyword>
</DOC>